IMRX
Immuneering Corporation
7.92
USD
This page is just a preview of the data found in TrendSpider’s full version
Immuneering Corporation stock is up 32.89% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 November’s closed higher than October.
Immuneering Corporation focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer.
